TD Asset Management Inc Decreases Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

TD Asset Management Inc lowered its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 60.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,880 shares of the company’s stock after selling 155,938 shares during the quarter. TD Asset Management Inc owned 0.14% of Zentalis Pharmaceuticals worth $421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Eventide Asset Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 47.9% in the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after acquiring an additional 3,745,936 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after acquiring an additional 585,644 shares during the period. Decheng Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth $31,809,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Zentalis Pharmaceuticals by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after acquiring an additional 3,759 shares during the period. Finally, Rafferty Asset Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 79.4% in the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock worth $5,456,000 after acquiring an additional 159,439 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ZNTL. Morgan Stanley reaffirmed an “equal weight” rating and issued a $8.00 price objective (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Stifel Nicolaus cut their price target on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, June 18th. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a report on Monday, August 12th. Oppenheimer cut their price target on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, June 18th. Finally, UBS Group lowered Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $28.00 to $5.00 in a report on Thursday, June 20th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $11.33.

Zentalis Pharmaceuticals Stock Up 2.9 %

Shares of Zentalis Pharmaceuticals stock opened at $3.24 on Monday. The stock’s 50-day simple moving average is $3.55 and its 200-day simple moving average is $8.69. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.83 and a 52 week high of $24.97. The company has a market capitalization of $230.12 million, a price-to-earnings ratio of -0.97 and a beta of 1.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same quarter last year, the firm posted ($1.85) earnings per share. On average, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.95 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.